Skip to content

Pibrentasvir

Mavyret, Maviret (pibrentasvir) is a small molecule pharmaceutical. Pibrentasvir was first approved as Mavyret on 2017-07-26. It is used to treat hepatitis c in the USA. It has been approved in Europe to treat chronic hepatitis c. Mavyret's patents are valid until 2035-06-05 (FDA).
Trade Name Maviret
Common Name Pibrentasvir
Indication chronic hepatitis c, hepatitis c
Drug Class Antivirals: NS5A inhibitors
Pibrentasvir
Get full access now